« Zurück
Startseite /
Rosiglitazone (maleate)

Rosiglitazone (maleate)

ArtNr	HY-14600-100mg
Hersteller	MedChem Express
CAS-Nr.	155141-29-0
Menge	100 mg
Quantity options	100 mg 10 mM/1 mL 200 mg 500 mg 50 mg
Kategorie	Oncology Neuroscience Neural Lineage Markers Metabolism Diabetes Glucose Homeostasis Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules By Organ Brain Cancer Neuronal Cell Markers
Typ	Inhibitors
Specific against	other
Purity	99.73
Citations	[1]Lehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6.\|[2]Willson TM, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8.\|[3]Thouennon E, et al. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J Neurochem. 2015 Aug;134(3):463-70.\|[4]Majeed Y, et al. Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Mol Pharmacol. 2011 Jun;79(6):1023-30.\|[5]Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar;96(3):215-220. Front Mol Biosci. 2022 Feb 4;8:766887.\|Pharmaceuticals. 2022, 15(9), 1055.\|Research Square Preprint. 2024 Feb 7.\|Acta Pharmacol Sin. 2023 May 24.\|Adipocyte. 2021 Dec;10(1):646-657.\|Adv Sci (Weinh). 2023 Jul 10;e2301088.\|Adv Sci (Weinh). 2025 Jan 30:e2413962.\|Adv Sci (Weinh). 2025 Mar 17:e2408724.\|Am J Physiol Endocrinol Metab. 2024 Apr 3.\|Am J Cancer Res. 2020 Apr 1;10(4):1182-1193.\|Antioxidants (Basel). 2024 Nov 24.\|Aquaculture. 2024 Jan 15, 578, 740081.\|Biochem Biophys Res Commun. 2020 Mar 26;524(1):70-76.\|Biochem Biophys Res Commun. 2024 Nov 26.\|Biochemistry (Mosc). 2021 May;86(5):568-576.\|Biochim Biophys Acta Mol Cell Biol Lipids . 2020 Aug;1865(8):158711.\|Biomed Pharmacother. 2020 Sep;129:110356.\|Biomed Pharmacother. October 2022, 113653.\|Biomedicines. 2021, 9(6), 677.\|Bioorg Chem. 7 October 2022, 106191.\|Bioorgan Med Chem. 15 February 2022, 116615.\|BMC Gastroenterol. 2025 Jan 20;25(1):22.\|Br J Pharmacol. 2020 May;177(10):2286-2302.\|Cancer Cell Int. 2023 Aug 11;23(1):164.\|Cancer Cell. 2024 May 13;42(5):869-884.e9.\|Cancer Res. 2022 Apr 15;82(8):1503-1517.\|Carcinogenesis. 2023 Mar 31;bgad015.\|Cell Commun Signal. 2023 Sep 30;21(1):268.\|Cell Death Differ. 2022 Nov 3.\|Cell Death Dis. 2023 Apr 6;14(4):246.\|Cell Death Dis. 2023 Dec 8;14(12):810.\|Cell Death Dis. 2024 Sep 29;15(9):695.\|Cell Death Dis.2024 May 21;15(5):350.\|Cell Death Discov. 2022 Apr 30;8(1):236.\|Cell Metab. 2021 Mar 2;33(3):581-597.e9.\|Cell Metab. 2023 Dec 5;35(12):2165-2182.e7.\|Cell Metab. 2023 Sep 7;S1550-4131(23)00304-2.\|Cell Mol Biol Lett. 2022 Feb 2;27(1):11.\|Cell Prolif. 2023 Jun 15;e13520.\|Cell Rep. 2025 Jan 30;44(2):115251.\|Cell Signal. 2022 Mar 6;110299.\|Cells. 2022, 11(1), 86.\|Chem Eng J. 2023 Aug 6, 145212.\|Chinese Pharmacological Bulletin. 2017, 33(4): 517-521. \|Circulation. 2022 Nov 30.\|CNS Neurosci Ther. 2024 Nov;30(11):e70081.\|Commun Biol. 2024 Apr 9;7(1):429.\|Drug Dev Res. 2023 Apr 13.\|Ecotoxicol Environ Saf. 2022 Jun 15;238:113611.\|Ecotoxicol Environ Saf. 2025 Jan 22:290:117765.\|Endocr J. 2021 Oct 29.\|Environ Int. 2023 Nov 25, 108354.\|Eur J Med Chem. 2021 Aug 25;225:113807.\|Eur J Med Chem. 2025 Jan 15:286:117284.\|Eur J Med Chem. 5 February 2022, 114061.\|Eur J Pharmacol. 2019 Jan 15;843:134-144.\|Eur J Pharmacol. 2020 Sep 5;882:173300.\|Eur J Pharmacol. 2022 Jul 31;175175.\|Eur J Pharmacol. 2023 Oct 12:176113.\|Eur J Pharmacol. 2025 Mar 5:996:177445.\|Food Funct. 2019 Dec 11;10(12):7983-7994.\|Food Science and Human Wellness. 2023 Nov;12(6);2061-2072.\|Free Radic Biol Med. 2018 Aug 21;126:259-268. \|Front Cell Dev Biol. 2020 Jul 29;8:703.\|Front Mol Neurosci. 2017 Sep 14;10:293.\|Front Pharmacol. 2022 Jun 27;13:919202.\|Front Physiol. 2019 Mar 1;10:165.\|Front Vet Sci. 2023 Nov 17:10:1277586.\|hLife. 2024 Mar 2.\|Immunol Invest. 2021 Apr 8;1-18.\|Inflamm Res. 2024 Aug 7.\|Int Immunopharmacol. 2021 Jan;90:107150.\|iScience. 10 October 2022, 105319.\|iScience. 2023 Feb 28;26(4):106289.\|J Biol Chem. 2024 Sep 12:107765.\|J Cardiovasc Transl Res. 2024 Jul 9.\|J Cell Mol Med. 2019 Oct;23(10):7029-7042. \|J Cell Physiol. 2019 Nov;234(11):20694-20703. \|J Ethnopharmacol. 2023 Dec 6:117550.\|J Exp Clin Cancer Res. 2024 Dec 19;43(1):324.\|J Exp Med. 2022 May 2;219(5):e20211906.\|J Nanobiotechnology. 2025 Jan 29;23(1):60.\|J Pharm Anal. 2025 Jan 3.\|J Physiol Biochem. 2022 May;78(2):377-388.\|J Therm Biol. 2024 Jul 2:123:103906.\|J Zhejiang Univ Sci B. 2020 Dec; 21(12): 990–998.\|Kidney Blood Press Res. 2021 Jul 28;1-12.\|Life Sci. 2021 Jan 5;119013.\|Mol Med. 2024 Nov 20;30(1):223.\|Mol Metab. 2024 Oct 29:102053.\|Molecules. 2024 Oct 15;29(20):4881.\|Nat Commun. 2023 Jun 2;14(1):3208.\|Nat Commun. 2023 May 15;14(1):2779.\|Neuromolecular Med. 2025 Jan 27;27(1):12.\|Nutrients. 2025 Feb 25.\|Ocul Surf. 2024 Oct 10:S1542-0124(24)00108-3.\|Oxid Med Cell Longev. 2021 Oct 14;2021:5527137.\|Patent. US20180263995A1.\|Pharmacol Res. 2020 Mar;153:104679.\|Phytother Res. 2022 Nov 3.\|PPAR Res. 2023 Nov 8:2023:6422804.\|PPAR Res. 28 Sept 2022.\|PPAR Res. 2019 Jul 1;2019:2715176. \|Preprints. 2024 Aug 23.\|Prog Neuropsychopharmacol Biol Psychiatry. 2023 Mar 25;110758.\|Redox Biol. 2023 Jun.\|Ren Fail. 2022 Dec;44(1):2056-2065.\|Reprod Domest Anim. 2023 Sep 15.\|Research Square Print. 2022 Aug.\|Sci Rep. 2024 Apr 30;14(1):9960.\|Sci Total Environ. 2023 May 16;888:164073.\|Sci Total Environ. 27 October 2022, 159755.\|Stem Cell Res Ther. 2024 May 1;15(1):127.\|Stem Cells Dev. 2022 Sep 21.\|Theranostics. 2022 Jan 24;12(4):1904-1920.\|Theranostics. 2022 Nov 7;12(18):7699-7716.
Smiles	O=C(O)/C=C\C(O)=O.CN(CCOC1=CC=C(CC2C(NC(S2)=O)=O)C=C1)C3=CC=CC=N3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BRL 49653C
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	Autophagy; Ferroptosis; PPAR; TRP Channel
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	473.50
Product Description	Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of PPARγ, with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a Kd of appr 40 nM for PPARγ; Rosiglitazone maleate is also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).
Manufacturer - Research Area	Cancer; Metabolic Disease; Inflammation/Immunology
Solubility	DMSO: 100 mg/mL (ultrasonic)\|H2O: < 0.1 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Autophagy; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Vitamin D Related/Nuclear Receptor
Isoform	PPARγ
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-14600-100mg-safety-datasheet.pdf